| Filed On | Filing |
|---|---|
| 28 Sep 2026 |
8-K: Other Events
On September 25, 2026, Gossamer Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price ... |
| 23 Sep 2026 |
8-K: Other Events
On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arteri... |
| 16 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
SAN DIEGO — (BUSINESS WIRE) — September 16, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hype... |
| 11 Sep 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
SAN DIEGO—(BUSINESS WIRE)— September 11, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment... |
| 09 Sep 2026 |
8-K: Other Events
SAN DIEGO—(BUSINESS WIRE)— September 9, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment ... |
| 03 Sep 2026 | 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year |
| 26 Aug 2026 | 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year |
| 21 Aug 2026 | 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more |
| 13 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 27 Jul 2026 | 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more |
| 15 Jul 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more |
| 01 Jul 2026 | 8-K: Regulation FD Disclosure |
| 17 Jun 2026 | 8-K: Regulation FD Disclosure |
| 05 Jun 2026 | 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more |
| 05 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 02 Jun 2026 | 8-K: Other Events |
| 18 May 2026 | 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +3 more |
| 09 Apr 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 17 Mar 2026 | 8-K: Results of Operations and Financial Condition |
| 23 Feb 2026 | 8-K: Other Events |
Loading...
